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Foreword
Dear Colleagues
Welcome to the 8th Conference of the Serbian Biochemical Society, entitled 
"Coordination in Biochemistry and Life".
The title of this year’s Conference refers to an important place of coordination
chemistry in biochemistry and biomedicine, but also to a need to coordinate the efforts 
towards new knowledge with fellow scientists from other fields in order to reach more. 
The collaboration within FEBS3+ (Croatia, Hungary, Slovenia, and Serbia) Meeting 
Programme continues with the invited lecture of our dear colleague Tantos Ágnes from 
Research Center for Natural Sciences, Budapest, Hungary. For the first time we have 
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biochemistry who is now affiliated at the Université de Bordeaux. We have more than 
forty PhD students from Serbia, Hungary, and Belarus with poster presentations, and for 
the first time the Conference is held outside the capital. It believe that we are getting better 
each year, and that we are prepared for future challenges.
I would like to express my gratitude to the members of the Scientific Board who 
suggested lecturers, to all respected colleagues who accepted the invitation, and to our dear 
hosts from the University of Novi Sad.
Editor of the Proceedings
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The sublingual route of allergens administration in allergen-specific immunotherapy 
(ASIT) is proven to be a successful way to treat patients with respiratory allergy. The trend 
of replacing natural extracts with purified recombinant allergens is growing. Although the 
purified allergens themselves are not good immunogens, the combined vector systems and 
adjuvans can improve their immunogenicity 1. Cell surfaces are decorated by different 
glycan structures, so the lectins specific for these glycans can be used to deliver particular 
therapeutic to target specific tissue 2. Banana lectin (BanLec) is mannose-specific protein 
which belongs to the subfamily of Jacalin-related lectins 3. Apart from its characteristic to 
bind glycans, BanLec also modulates immune cells in vitro 4. On the other hand, Bet v 1 
(Betula verrucosa) is the major birch pollen allergen. T-cell epitops are distributed over 
almost entire protein structure 5.
In the study the recombinant BanLec-Bet v 1 construct is designed, produced by the 
recombinant DNA technology, purified and characterized by classical biochemical 
methods for the application in the ASIT of birch pollen allergy. 
The expression of newly designed BanLec-Bet v 1 was performed in E. coli BL21 (DE3). 
After expression the protein was found in the inclusion bodies from which it was extracted 
with 4 M urea solution. After renaturation, affinity chromatography (Sephadex G-75
superfine) was used for protein purification. Biochemical characterization of the chimera 
was performed by: SDS PAGE electrophoreses, CD spectroscopy and mass spectrometry. 
Biological activity of the construct was confirmed by binding of BanLecBet v 1 to a
horseradish peroxidase glycoprotein in ELISA. Purified BanLec-Bet v 1 showed molecular 
mass of 32 kDa. CD spectra of the recombinant construct revealed well defined secondary 
structures with predominant beta sheets (41.2%). By mass spectrometry 51.8% of the 
BanLec-Bet v 1 primary structure was confirmed.
Biologicaly active recombinant BanLec-Bet v 1 was produced by the recombinant DNA 
technology. Further in vitro and in vivo studies will evaluate immunomodulatory potential 
of BanLec-Bet v 1 for application in ASIT.
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